Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Wyeth

Status and phase: Terminated; Phase 1

Conditions: Tumors; Neoplasms

Treatments: Drug: TTI-237

Study type: Interventional

Funder types: Industry

Identifiers

NCT00195325

3162K1-100

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Documented diagnosis of malignant solid tumor with measurable disease
• Life expectancy of at least 12 weeks
• ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2

Exclusion criteria

• Recent major surgery, radiation therapy or anti-cancer treatment
• History of any other prior malignancy within the last 5 years

Trial design

Primary purpose: Educational/Counseling/Training

Allocation: Non-Randomized

Interventional model: Factorial Assignment

Masking: None (Open label)